Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China

Table 2 Data summary of patients with HIV-HBV coinfection before and after liver transplantation

Case	Age (year)	sex	Indication for OLT	HIV CDC classification Pre-OLT	CD4 cell count (cells/ul) Pre-OLT	HIV-RNA (copies/ml) Pre-OLT	HBV-DNA (copies/ml) Pre-OLT	MELD score	HAART Pre-OLT	Latest CD4 cell count (cells/ul)	Latest HIV-RNA (copies/ml)	Latest HBV-DNA (copies/ml)	HAART after OLT	Hospital stays (d)	Complications	Follow-up (mo)	Outcome
1	61	Male	HBV-ACLF	A3	42	ND	4.23E + 06	40	DTG + 3TC + TAF	209	ND	< 20	DTG + 3TC + TAF	37	Acute rejection	43	Alive
2	52	Male	HBV-DLC	C3	140	< 500	6.71E + 02	10	FTC + TAF + RAL	317	ND	< 20	FTC + TAF + RAL	18	No	39	Alive
3	47	Male	HBV-ACLF	A3	181	< 500	4.51E + 04	35	TAF + FTC + DTG	478	< 250	< 20	TAF + FTC + DTG	39	No	37	Alive
4	46	Male	HBV-ACLF	A3	121	< 500	< 200	40	DTG + ABT	476	ND	< 20	DTG + ABT + TAF	64	No	36	Alive
5	34	Male	HBV-ACLF	A3	113	< 500	< 200	31	3TC + DTG	244	< 250	< 20	B/F/TAF	31	No	15	Alive
6	65	Male	HBV-ACLF	A3	165	< 500	2.53E + 04	34	TDF + FTC + RAL	231	< 250	< 100	TDF + FTC + RAL	31	No	12	Alive
7	58	Male	HBV-ACLF	A3	38	< 500	< 100	31	3TC + DTG	3	< 500	< 100	DTG + ABT + TAF	66	Pulmonary infections, acute renal failure	2	Dead

Abbreviations: 3TC, lamivudine; ACLF, acute-on-chronic liver failure; ABT, Albuvirtide; B/F/TAF, Bictegravir/emtricitabine/tenofovir alafenamide; DLC, decompensated liver cirrhosis; DTG, dolutegravir; FTC: Emtricitabine; HIV, human immunodeficiency virus; HBV, hepatitis B virus; MELD, model for end stage liver disease; OLT, orthotopic liver transplantation; RAL, Raltegravir; TAF, tenofovir alafenamide; TDF, Tenofovir disoproxil fumarate; IQR, Interquartile range; ND, Not detectable;

ISSN: 1471-2334